A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer (NCT07227168)
A Phase 1 Open-Label Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of STRO-004 in Adults With Refractory/Recurrent Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a cohort expansion in 1 or more types of cancer to further evaluate a STRO-004 monotherapy dose, determine the best dose for use in later phases, and examine anti-tumor activity. * Part 1C is a dose escalation of STRO-004 combined with pembrolizumab to determine tolerability and preliminary anti-tumor activity of both drugs used together.
Who can join: Review the eligibility criteria below.
Location: UC San Diego Moores Cancer Center — San Diego, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- UC San Diego Moores Cancer Center — San Diego, California
- SCRI Denver — Denver, Colorado
- Georgetown University Medical Center — Washington D.C., District of Columbia
- SCRI FCS Sarasota — Sarasota, Florida
- Mass General Cancer Center — Boston, Massachusetts
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai — New York, New York
- NEXT Austin — Austin, Texas
- NEXT San Antonio — San Antonio, Texas
- NEXT Virginia — Fairfax, Virginia
📞 Contact the Study Coordinator
Phone: (650) 801-6416
Email: ClinicalTrials@sutrobio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Head and Neck Squamous Cell Carcinoma HNSCC clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.